Feb 09, 2023 / 08:55PM GMT
Charles Zhu - Guggenheim Securities, LLC - Analyst
Good afternoon, everyone. I am Charles Zhu, one of the senior biotech analysts at Guggenheim Securities. Thank you all for joining us. For our next and last session for today, we are joined by Fahar from Medicenna. Fahar, thank you so much for participating at our conference today. We really appreciate it.
Perhaps just to kick us off, could you provide us an overview of your company platform and pipeline, please?
Fahar Merchant - Medicenna Therapeutics Corp. - President & CEO
Yes. Thank you, Charles. Thank you, first and foremost, for inviting us to be here today and it's obviously a great, great event.
So very briefly, Medicenna's focus has been essentially around a platform, we call that Superkines. Those Superkines are based on three different interleukins, namely Interleukin 2, 4, and 13. And these different interleukins have been generated. So there's a whole library of these interleukins where using a combination of use display together with a directed evolution, just come up with a
Medicenna Therapeutics Corp at Guggenheim Healthcare Talks Oncology Day Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers